Abstract: Methods and systems for enhancing the security of data during input and output on a client computer system are provided to prevent attempts by unauthorized code to access, intercept, and/or modify data. Example embodiments provide a plurality of obfuscation techniques and security enhanced drivers that use these obfuscation techniques to prohibit unauthorized viewing/receiving of valid data. When the drivers are used together with the various obfuscation techniques, the security enhanced drivers provide mechanisms for “scheduling” the content of the storage areas used to store the data so that valid data is not available to unauthorized recipients. When unauthorized recipients attempt to access the “data,” they perceive or receive obfuscated data. The obfuscation techniques described include “copy-in,” “replace and restore,” and “in-place replacement” de-obfuscation/re-obfuscation techniques.

Abstract: Compounds of formula (I), wherein R1, p, R2, q, R3 and R4 are defined within, and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.

Abstract: A new salt of a prodrug useful in antibody directed enzyme prodrug therapy (ADEPT) is disclosed. A hydrogen iodide salt of the prodrug N-(4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl)-L-glutamic acid is prepared which can be obtained in crystalline form. Preparation of the crystalline form of the prodrug enables preparation of the prodrug in highly pure form.